What Is HGH Fragment 176-191 Peptide?
HGH Fragment 176-191 is a peptide fragment derived from the C-terminal region of human growth hormone (somatotropin). It consists of the amino-acid residues at positions 176 through 191 of the parent hormone. PubChem and the NLM MeSH database classify it as somatotropin (176-191) and as a peptide fragment of growth hormone.
The compound is distinct from full-length human growth hormone because it represents only a defined portion of the parent protein. It is also chemically distinct from modified derivatives such as AOD-9604, which contains a different N-terminal residue and therefore is not the same peptide.
HGH Fragment 176-191 has been chemically synthesized and characterized in published peptide research. Early studies specifically examined synthetic C-terminal fragments of human growth hormone including the 176-191 sequence.
Research Overview Table
Chemical and Molecular Characteristics
HGH Fragment 176-191 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone. The structure contains two cysteine residues connected by an intramolecular disulfide bond, producing a defined cyclic region within the peptide chain.
The compound belongs to the somatotropin derived peptide fragment class. Its peptide backbone, amino acid side chains, stereochemistry and disulfide connectivity define its molecular architecture. and distinguish it from smaller chemical compounds and other growth hormone fragments. These structural features are relevant to maintaining consistent molecular identity and composition in laboratory research.
Certificates:
Mechanism of Action Under Investigation
The mechanism of HGH Fragment 176-191 remains unresolved. Published work on C-terminal human growth hormone fragments indicates that their activity may occur independently of the classical growth hormone receptor. Studies have reported low or absent interaction with the canonical growth hormone receptor compared with intact growth hormone.
Experimental studies of related C-terminal fragments have reported effects on adipocyte lipid metabolism. One proposed mechanism involves membrane-associated signaling followed by phosphorylation and inhibition of acetyl-CoA carboxylase, an enzyme involved in fatty-acid synthesis. However, these findings were obtained with related fragments and do not establish this pathway specifically for native HGH Fragment 176-191.
A definitive receptor or complete downstream signaling pathway for native HGH Fragment 176-191 has not been established. Therefore, proposed mechanisms remain experimental rather than confirmed.
Scientific Research Context
The published evidence for HGH Fragment 176-191 remains small and predominantly preclinical. Researchers have studied the native fragment mainly in animal and laboratory models. The literature also includes research on related C-terminal growth hormone fragments but these studies do not establish evidence for the native 176-191 sequence. Human clinical evidence for HGH Fragment 176-191 remains limited.
HGH Fragment 176-191 Biology and Biological Pathways
Primary Biological Function
Published research has not established a definitive physiological function for HGH Fragment 176-191. The primary study that directly tested hGH 176-191 found that the peptide produced a short lived increase in blood glucose and a more sustained increase in plasma insulin in normal rats. The study therefore identified glucose and insulin regulation as observed biological activity, rather than establishing a normal physiological role for the peptide.
Relevant Metabolic or Signalling Pathways
Studies directly involving hGH 176-191 examined glucose metabolism, glycogen metabolism and pyruvate metabolism. Researchers reported changes in glycogen synthase and pyruvate dehydrogenase activity after exposure to C-terminal hGH peptides. These findings identify metabolic processes associated with the peptide but do not establish a complete signaling pathway.
Tissue-Specific Biology
Published research has examined hGH 176-191 in relation to metabolic activity in liver, skeletal muscle and adipose tissue. The reported effects differed between tissues, particularly for glycogen synthase and pyruvate dehydrogenase activity. This tissue specific variation provides a basis for investigating how C-terminal hGH sequences interact with different metabolic systems.
Experimental Biomarkers
Direct studies of HGH Fragment 176-191 measured blood glucose and plasma insulin in rats. A later study that directly tested hGH 176-191 also measured blood lactate, glycogen synthase activity and pyruvate dehydrogenase activity. These markers were used to assess peptide-associated metabolic responses in experimental research.
Laboratory Investigation Methods
Researchers have used biochemical measurements of metabolic and enzymatic activity to examine C-terminal hGH peptides. Published studies have assessed blood glucose, plasma insulin, tissue enzyme activity and glucose metabolism. A later study also examined HGH Fragment 176-191 through molecular docking and cell based viability analysis, although that work investigated the peptide within a nanoparticle system.
Experimental Models Used in Published Research
Published research on HGH Fragment 176-191 includes a limited number of direct experimental models. These include normal rats, rat tissue preparations, human MCF-7 cells, and in-silico molecular models. Some studies used related C-terminal growth hormone sequences rather than the exact 176-191 peptide, so those models require separate interpretation.
Normal Rat Model
Researchers directly studied synthetic HGH Fragment 176-191 in normal rats in early in vivo research. This model provided whole-animal evidence for the peptide. Its main limitation is that rat physiology does not fully represent human biology. so findings from this model cannot be directly extrapolated to humans.
Rat Tissue Preparations
Published research examined HGH 176-191 in rat tissues, including liver, skeletal muscle, and adipose tissue. These preparations provide tissue-level models but do not reproduce the complete physiology of an intact organism.
Human MCF-7 Cells
Researchers studied HGH Fragment 176-191 in human MCF-7 breast cancer cells. This model is limited because MCF-7 cells represent a cancer derived cell line rather than normal human tissue and the study examined the peptide within a nanoparticle formulation.
In-Silico Molecular Models
Researchers used in silico molecular modeling to predict the three dimensional structure of HGH Fragment 176-191 and examine its potential interactions with selected breast cancer related proteins. The study used peptide structure prediction and molecular docking. This approach is limited because computational binding predictions do not demonstrate confirmed molecular interactions or biological activity in living systems.
Published Scientific Research
Metabolic Research
Research on HGH Fragment 176-191 has examined its biological activity in relation to glucose and insulin physiology. Studies have also investigated its effects on glycogen and pyruvate metabolism as part of research into C-terminal sequences of human growth hormone.
C-Terminal Sequence Research
Researchers have investigated whether specific C-terminal sequences of human growth hormone contribute to distinct biological activity. HGH Fragment 176-191 was studied alongside closely related sequences. allowing researchers to examine how changes in the C-terminal peptide sequence relate to biological activity.
Cellular and Molecular Research
More recent research has investigated HGH Fragment 176-191 in cellular and molecular applications. One study examined the peptide in combination with doxorubicin loaded chitosan nanoparticles and investigated predicted interactions with selected molecular targets. This represents a separate research direction from the earlier metabolic studies.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The direct evidence for HGH Fragment 176-191 remains limited and predominantly preclinical. The clearest compound-specific study used normal rats. Later research has also examined the peptide in laboratory settings. This evidence base does not provide sufficient human data to establish conclusions about the native peptide.
Human Clinical Evidence
No human clinical study of the unmodified HGH Fragment 176-191 was identified in the reviewed literature. Human studies commonly associated with this peptide involve AOD-9604, a structurally distinct analogue. Those findings should not be treated as direct clinical evidence for native HGH Fragment 176-191.
Species Differences
Direct animal research provides evidence from rat systems, but species differences can affect peptide biology and physiological responses. Findings from rats therefore cannot be assumed to represent human responses. This limitation becomes particularly important because direct human evidence for the native fragment remains absent.
Study Design Limitations
Several publications investigate related C-terminal growth hormone sequences rather than exclusively testing HGH Fragment 176-191. Differences between sequences make direct attribution difficult. In addition, the available literature includes early experimental work and a later cellular study using a nanoparticle formulation. creating substantial differences between study designs.
Independent Replication
The compound-specific literature remains small. Direct evidence comes from a limited number of publications. while much of the surrounding literature concerns related C-terminal fragments or AOD-9604. This limited replication makes it difficult to determine whether individual observations remain consistent across independent research groups and experimental approaches.
Long-Term Evidence
The reviewed literature does not provide a substantial long-term evidence base for native HGH Fragment 176-191. Available direct research is largely experimental and does not establish long term biological effects in humans. Consequently, conclusions about prolonged exposure to the unmodified peptide remain unsupported by adequate published evidence.
Analytical Documentation
HPLC separates peptide components and evaluates chromatographic purity, allowing laboratories to assess the presence of related impurities or degradation products. LC-MS measures molecular mass and supports peptide identity and impurity characterization. NMR, where appropriate, provides additional structural information about peptide composition and conformation.
A Certificate of Analysis (CoA) documents analytical results for a specific batch and may report identity, purity, and other defined quality specifications. Analytical documentation gives researchers traceable information about the material used in laboratory work and helps confirm compliance with established quality criteria. These analytical data verify product identity and quality, not biological performance.
Storage and Laboratory Handling
Store HGH Fragment 176-191 at 2–8°C, as specified on the Certificate of Analysis. Qualified laboratory personnel should handle the material using appropriate laboratory practices. Keep the material protected from contamination during storage and handling.
Use clean laboratory equipment and maintain suitable conditions when handling the material. Return the material to the specified storage conditions when not in use. HGH Fragment 176-191 is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.